Trial Profile
Dose Finding Study for Sugammadex and Neostigmine at Residual Neuromuscular Blockade (T4/T1 = 0.2)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Oct 2022
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary) ; Neostigmine
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- Acronyms SUNDRO20
- 09 Feb 2016 New trial record
- 01 Feb 2016 Results published in the British Journal of Anaesthesia